Skip to main content
OpenTrials

Clinical trial condition

Parkinson Disease

Explore clinical trials studying Parkinson Disease. Study availability and eligibility vary by location and protocol.

1,814 public trials 369 recruiting studies
Refine in advanced search Browse all conditions

Parkinson Disease trial results

Completed

Special Survey on Parkinson's Disease (PD) Patients Without Concomitant Use of L-Dopa

NCT00613301

Conditions
Basal Ganglia Diseases, Brain Diseases, Central Nervous System Diseases, +6 more
Locations
  • Boehringer Ingelheim Investigational Site 11 Akita, Japan
  • Boehringer Ingelheim Investigational Site 95 Anan, Japan
  • Boehringer Ingelheim Investigational Site 1 Asahikawa, Japan
  • Boehringer Ingelheim Investigational Site 2 Asahikawa, Japan
View all 119 locations
View Trial Details
Completed

Safety of Urate Elevation in Parkinson's Disease

NCT00833690

Conditions
Basal Ganglia Diseases, Brain Diseases, Central Nervous System Diseases, +6 more
Locations
  • University of Southern California Los Angeles, California, United States
  • Eastern Connecticut Neurology Specialists, LLC Manchester, Connecticut, United States
  • Institute for Neurodegenerative Disorders New Haven, Connecticut, United States
  • Parkinson's Disease and Movement Disorders Center of Boca Raton Boca Raton, Florida, United States
View all 16 locations
View Trial Details
Completed

Non-motor Symptoms (Depressive Symptoms) of Parkinson's Disease and Their Course Under Pramipexole Treatment

NCT00651183

Conditions
Basal Ganglia Diseases, Brain Diseases, Central Nervous System Diseases, +6 more
Locations
  • Boehringer Ingelheim Investigational Site Amstetten, Austria
  • Boehringer Ingelheim Investigational Site Bad Hall, Austria
  • Boehringer Ingelheim Investigational Site Bad Ischl, Austria
  • Boehringer Ingelheim Investigational Site Bad Radkersburg, Austria
View all 57 locations
View Trial Details
Completed

Long-term Safety Study of Open-label Pramipexole ER in Patients With Advanced PD

NCT00577460

Conditions
Basal Ganglia Diseases, Brain Diseases, Central Nervous System Diseases, +6 more
Locations
  • 248.634.43005 Boehringer Ingelheim Investigational Site Linz, Austria
  • 248.634.42003 Boehringer Ingelheim Investigational Site Pardubice, Czechia
  • 248.634.42001 Boehringer Ingelheim Investigational Site Prague, Czechia
  • 248.634.42005 Boehringer Ingelheim Investigational Site Rakovník, Czechia
View all 70 locations
View Trial Details
Completed

a PMS on Safety Profile of Pramipexole in Chinese Parkinson Disease Patients

NCT01361009

Conditions
Basal Ganglia Diseases, Brain Diseases, Central Nervous System Diseases, +6 more
Locations
  • Boehringer Ingelheim Investigational Site 54 Beijing, China
  • Boehringer Ingelheim Investigational Site 55 Beijing, China
  • Boehringer Ingelheim Investigational Site 56 Beijing, China
  • Boehringer Ingelheim Investigational Site 57 Beijing, China
View all 103 locations
View Trial Details
Completed

Overnight Switch Trial From Pramipexole IR to Pramipexole ER in Patients With Early Parkinson Disease

NCT00558025

Conditions
Basal Ganglia Diseases, Brain Diseases, Central Nervous System Diseases, +6 more
Locations
  • 248.636.3303A Boehringer Ingelheim Investigational Site Aix-en-Provence, France
  • 248.636.3303B Boehringer Ingelheim Investigational Site Aix-en-Provence, France
  • 248.636.3303C Boehringer Ingelheim Investigational Site Aix-en-Provence, France
  • 248.636.3307C Boehringer Ingelheim Investigational Site Bron, France
View all 36 locations
View Trial Details
Completed

Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD)

NCT00321854

Conditions
Basal Ganglia Diseases, Brain Diseases, Central Nervous System Diseases, +6 more
Locations
  • 248.595.0122 Boehringer Ingelheim Investigational Site Brimingham, Alabama, United States
  • 248.595.0104 Boehringer Ingelheim Investigational Site Scottsdale, Arizona, United States
  • 248.595.0133 Boehringer Ingelheim Investigational Site La Jolla, California, United States
  • 248.595.0140 Boehringer Ingelheim Investigational Site La Jolla, California, United States
View all 99 locations
View Trial Details
Completed

A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over 12-week Treatment in Early Parkinson's Disease (PD) Patients

NCT00402233

Conditions
Basal Ganglia Diseases, Brain Diseases, Central Nervous System Diseases, +6 more
Locations
  • 248.622.170 Boehringer Ingelheim Investigational Site Phoenix, Arizona, United States
  • 248.622.112 Boehringer Ingelheim Investigational Site Little Rock, Arkansas, United States
  • 248.622.69 Boehringer Ingelheim Investigational Site Fountain Valley, California, United States
  • 248.622.198 Boehringer Ingelheim Investigational Site La Jolla, California, United States
View all 39 locations
View Trial Details

Related conditions